- 专利标题: Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
-
申请号: US16413335申请日: 2019-05-15
-
公开(公告)号: US11180545B2公开(公告)日: 2021-11-23
- 发明人: Jan Grimm , Aubin Michalon
- 申请人: Neurimmune Holding AG
- 申请人地址: CH Schlieren
- 专利权人: Neurimmune Holding AG
- 当前专利权人: Neurimmune Holding AG
- 当前专利权人地址: CH Schlieren
- 代理机构: Clark & Elbing LLP
- 代理商 Susan M. Michaud
- 优先权: EP13199251 20131220
- 主分类号: A61K39/00
- IPC分类号: A61K39/00 ; A61K39/395 ; A61K38/17 ; C07K16/18 ; G01N33/68
摘要:
Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to antibodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
信息查询